Taken together, these results demonstrate that PLP-CD8 employ an ordered regulatory program over a number of days in vivo to suppress pathogenic PLP-specific CD4 T cell responses and inhibit demyelinating disease. This evidence concerns the gene PLP1 and demyelinating disease.